What should I do if the price of pemetinib/pemetinib is too expensive?

Pemigatinib (Pemigatinib), as an innovative drug targeting FGFR2 fusion or rearrangement, has shown important value in the treatment of cholangiocarcinoma (CCA) and some hematological tumors. Its clinical application fills the gap of limited traditional treatment methods and provides patients with new options for precise targeted treatment. However, the prices of this type of new targeted drugs are generally high, especially when they are not yet included in domestic medical insurance. A box of drugs can cost between RMB 20,000 and RMB 50,000, and the price in overseas markets is even higher. For ordinary patient families, the burden of long-term treatment is heavy, so how to deal with high drug prices has become a practical problem.

Faced with high drug prices, patients and families can adopt a variety of strategies to ease the financial pressure. First, you can focus on drug reimbursement and assistance programs. Although pemetinib has not yet been included in medical insurance in China, some manufacturers or foundations provide patient assistance programs that cover part of the drug cost or provide preferential purchase channels. Secondly, generic drugs can be obtained through formal overseas channels. The generic drugs produced in some countries on the market have basically the same ingredients as the original drugs, and the prices are much lower than the original drugs. For example, the 4.5 mg drug produced by Lucius Pharmaceuticals in Laos sells for about more than 700 yuan per box, which provides an economically feasible option for some patients, but it must be purchased through legal channels to ensure drug quality and safety.

In addition, patients should maintain close communication with clinicians. In some cases, doctors will adjust the treatment plan according to the condition and tolerance, and combine the dosage and treatment schedule to optimize the use of drugs, thereby reducing unnecessary expenses while ensuring the efficacy. It is worth noting that the financial burden of high-priced drugs should not affect treatment compliance, and patients should avoid voluntary dose reductions or arbitrary discontinuation of drugs, which may lead to reduced efficacy or disease progression.

Reference materials:https://go.drugbank.com/drugs/DB15102